SAGE Cardiology and Cardiovascular Medicine

SAGE Cardiology and Cardiovascular Medicine

  • 概覽
  • 聲音
概覽
himalaya
18 聲音
Welcome to the official free Podcast from SAGE for Cardiology & Cardiovascular Medicine.SAGE is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets with principal offices in Los Angeles, London, New Delhi, and Singapore.
查看更多
聲音
18聲音

Dr. Ross Hanson and Dr. Andi Chatburn discuss the ethical and legal implications of changes to traditional standards of care during the COVID-19 pandemic.

Dr. Ross Hanson and Dr. Stephanie Jones discuss integration of anesthesiology into the critical care and hospital response to the COVID-19 pandemic.

The 3-factor prothrombin complex concentrate (3FPCC) may be used off-label to treat refractory bleeding during cardiac surgery in children. This retrospective study examined the rate of clinical complications following the use of 3FPCC. Patients treated with 3FPCC were matched to controls for age, gender, prematurity, weight, cardiopulmonary bypass times, and cross-clamp times. Fifty-nine cases were individually matched to 59 controls based on propensity scores. 3FPCC was not associated with an increased risk of thromboembolic events, mortality, or need for postoperative extracorporeal membrane oxygenator support. These results suggest the safety of 3FPCC when used for refractory bleeding after cardiopulmonary bypass in children undergoing congenital heart surgery. To view the article,click here.

SCVAEditorial Board member and Director of Pediatric Cardiothoracic Anesthesiology, Dr. Gregory Latham, discusses the importance of meeting abstracts and highlights a few abstracts from the CCAS 2019 annual meeting, while providing an overview of the remaining abstracts.

In this article, the authors present the annual review of the literature relevant for the practice of cardiovascular critical care. This is not an exhaustive review of the year, but rather selected highlights to summarize contributions to the literature since our last review. The topics covered this year include advances in the reversal of anticoagulants, introduction of a new class of vasopressor, innovative measures of acute kidney injury risk and presence after cardiac surgery, use of bicarbonate in severe acidosis, and finally, new information regarding the ongoing drug shortage issue. To view the article,click here.

The anesthesia community has openly debated if the care of transplant patients was generalist or specialist care ever since the publication of an opinion paper in 1999 recommended subspecialty training in the field of liver transplantation anesthesia. In the past decade, liver transplant anesthesia has become more complex with a sicker patient population and evolving evidence-based practices. Transplant training is currently not required for accreditation or certification in anesthesiology, and not all anesthesia residency programs are associated with transplant centers. Yet there is evidence that patient outcome is affected by the experience of the anesthesiologist with liver transplants as part of a multidisciplinary care team. Requests for a formal review of the inequities in training opportunities and requirements led the Society for the Advancement for Transplant Anesthesia (SATA) to begin the task of developing post-graduate fellowship training recommendations. In this article...

Anesthesia providers are frequently exposed to radiation during routine patient care in the operating room and remote anesthetizing locations. Eighty-two percent of anesthesiology residents (n = 57 responders) at our institution had a “high” or “very high” concern about the level of ionizing radiation exposure, and 94% indicated interest in educational materials about radiation safety. This article highlights key learning points related to basic physical principles, effects of ionizing radiation, radiation exposure measurement, occupational dose limits, considerations during pregnancy, sources of exposure, factors affecting occupational exposure such as positioning and shielding, and monitoring. Continued education and awareness of the risks of ionizing radiation and protective strategies will reduce exposure and potential for associated sequelae. To view the article, click here.

More than 3000 peer-reviewed publications on the topic of liver transplantation were published in 2016. The goal of this article is to provide a concise review of pertinent literature for anesthesiologists who participate in liver transplantation. The authors selected and presented 33 articles published in 2016 on the topics of MELD policy; cardiovascular, pulmonary, and renal issues; coagulation and transfusion; anesthetic agents; hemodynamic monitors; acute liver failure; and donor issues. To view the article, click here.

Nathaen Weitzel, one of the Editors-in-Chief of SCVA, talks to Ernesto Pretto of The Society for the Advancement of Transplant Anesthesia (SATA).They discuss transplant anesthesia and highlight howSeminars in Cardiothoracic and Vascular Anesthesia will now serve as the official home journal for SATA. To view the SATA Editorial in the March 2017 issue of SCVA, click here.

Due to familiarity, short half-life, ease of monitoring, and the availability of a reversal agent, heparin remains the anticoagulant of choice for cardiac operations requiring cardiopulmonary bypass (CPB). However, occasionally patients require CPB but should not receive heparin, most often because of acute or subacute heparin-induced thrombocytopenia (HIT). In these cases, if it is not feasible to wait for the disappearance of HIT antibodies, an alternative anticoagulant must be selected. A number of non-heparin anticoagulant options have been explored. However, current recommendations suggest the use of a direct thrombin inhibitor such as bivalirudin. This review describes the use of heparin alternatives for the conduct of CPB with a focus on the direct thrombin inhibitors. To view the article, click here.

12
常見問題
  • Himalaya 是什麼?
    喜馬拉雅國際版,Himalaya 是一款有聲書 App,旨在為全球華人的終身學習提供隨時、隨地、隨心的全新聽書體驗。成為會員,即可以暢聽站內 100,000+ 海量會員內容。
  • Himalaya VIP 有什麼權益?
    你僅需花費每日低至 0.16 美金,就可以立即暢聽 100,000+ 全球銷量超百萬的暢銷有聲書,每週聽一本爆款新書,還有更多預售新書等著你!另可獲得每月 5 張免費體驗卡贈親友的福利,等同於贈送 1 張年卡的價值。
  • 我怎麼享受免費試用?
    現在訂閱 Himalaya VIP 即可享受至少 7 天的免費試用! 免費試用期內,無需付費即可免費暢聽會員包中的全部內容,包含 100,000+ 全球銷量超百萬的暢銷有聲書,和世界名校教授的原聲英文課程。
  • 我該怎麼使用優惠碼?
    在 Himalaya 首⻚選擇「開啟免費體驗」註冊完成之後, 輸入「優惠碼」選擇申請,支付成功後即可開啟 Himalaya VIP 內容免費暢聽權益!
  • 可以在哪收聽?
    Himalaya 提供你隨時隨地想听就听的服務, 可以下載 Himalaya APP 使用手機享受服務,同時也支持網頁版登陸在電腦上享受暢聽服務。
  • Himalaya VIP 的價格是多少?
    Himalaya VIP 採用連續訂閱的模式,按月訂閱價格為 $11.99/月;按年訂閱價格為 $59.99/年。每天僅需 0.16 美元,讓耳朵隨時隨地步入擁有 100,000+ 書籍你的專屬圖書館。
  • 我不想訂閱了,要如何取消?
    通過網頁端訂閱如何取消?
    你可以 點擊這裡 取消訂閱。 在試用期內取消訂閱,則不會自動續費;如果你已經成功續費後取消訂閱,則下個扣款週期不會自動續費。
    通過手機端訂閱如何取消?
    你可以在iTunes/Apple或Google Play設定中取消訂閱。在試用期到期前48小時取消訂閱,則不會自動續費;如果你已經成功續費後取消訂閱,則下個扣款週期不會自動續費。你可以通過以下連結找到如何取消訂閱的詳細資訊:Apple Store取消訂閱方法  Google Play取消訂閱方法

與Himalaya一起

每天15分鐘
在碎片的時間裡,學習一個知識點;通勤時、家務時、運動時,隨時隨地暢聽
每週1本新書
優選最新最熱暢銷書,資深編輯精心挑選榜單佳作,只聽有價值的好書
每年10大系列
商業財經、歷史文化、親子育兒,同系列好書好課一網打盡,帶你深入探究一個主題
app store
google play